FDA Oks Checkpoint Therapeutics' UNLOXCYT For Advanced Cutaneous Squamous Cell Carcinoma treatment

(RTTNews) - Checkpoint Therapeutics Inc. (CKPT) announced that the U.S. Food and Drug Administration (FDA) has approved UNLOXCYT(cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation. UNLOXCYT is the first and only programmed death ligand-1 (PD-L1) blocking antibody to receive FDA marketing approval for this indication.

The recommended commercial dosage of UNLOXCYT is 1,200 mg administered as an intravenous infusion over 60 minutes every three weeks.

Cutaneous squamous cell carcinoma (cSCC) is the second most common type of skin cancer in the United States, with an estimated annual incidence of approximately 1.8 million cases according to the Skin Cancer Foundation.

For More Such Health News, visit rttnews.com.